Kornimate/medical-research-clean huggingface dataset:
cross-sectional study of covid-19 infection in hospital health personnel

Conditions: SARS-CoV-2 Infection

Summary: the objective of the study is to determine the percentage of past sars-cov-2 infections in hospital health personnel involved in the care of people with covid-19 in hugtip and in badalona serveis assistencials de badalona.

health personnel, especially hospital workers, have been a group especially affected by the covid-19 epidemic. according to data from the ministry of health, in spain 26% of health personnel have been infected by covid-19, for a total of 31,053 professionals, representing up to 18.5% of all infections in the spanish state, with variations between the different autonomous communities.1 in italy it was estimated that up to 20% of health workers who responded to the epidemic would have been infected within a month. there are no unified guidelines at the state level to determine infection prevention strategies in health personnel in order to validate them, beyond the use of personal protective equipment (ppe) in personnel and general strategies for isolation and prevention of transmission. there are no approved drug prevention strategies for primary prophylaxis against covid-19. currently, there are no universal mass screening strategies (virological or immunological) to estimate the actual number of health personnel with an asymptomatic infection, as well as to determine the percentage of personnel who have already passed the infection asymptomatically or to determine the percentage of personnel a healthcare provider who has developed some form of immunity following a confirmed covid-19 infection. the hugtip, like the rest of catalan hospitals, has suffered a massive avalanche accumulated in the time of admission by covid-19, which has forced it to adopt different innovative strategies to visit them in emergencies, enter them in conventional hospitalization in a conventional plant, or attend them in the intensive care units that had to be created de novo against the clock. as of april 20, 2020, 1,000 hospital discharges have been granted to patients admitted by covid-19 in conventional hospitalization plants and 170 more discharges from those admitted to intensive care units at hugtip. likewise, the municipal hospital of badalona has given a total of 300 discharges of patients with covid-19, and they have also reported about 180 infections in their health personnel in this period. due to the high transmission rate of sars-cov-2 and its potential severity, several healthcare workers at hugtip decided on their own to take empirical primary prophylaxis with oral hydroxychloroquine individually as prevention of sars-cov-2 infection.

Eligibility criteria:
inclusion criteria: * adults (age\> 18 years) who have worked during the epidemic period (march and april 2020) in the infectious diseases, pneumology, emergencies, icu and internal medicine departments of hugtip, or in the internal medicine or emergency departments of the badalona municipal hospital. exclusion criteria: * participation will be voluntary and no exclusion criteria are established
combination of sorafenib and radiation for brain metastases and primary brain tumors

Conditions: Brain Metastases; Primary Brain Tumors

Summary: sorafenib™ has the potential to inhibit tumor growth, tumor angiogenesis , and enhance radiation response. this study will test the combination of sorafenib™ and radiation therapy with or without temozolomide to determine tolerance of the combined treatments. defining safe dosing of sorafenib™ in this combination therapy will be achieved.

the current standard of care for patients with brain metastatic malignancies is to receive radiation therapy alone, while the standard of care for patients with high grade primary brain malignancies, astrocytomas, is to receive to receive concurrent temozolomide with radiation therapy. in this phase i study, based on the range of efficacy of kinase inhibitors and its ability to cross the blood-brain barrier we will conduct two parallel studies. the first is to combine sorafenib and radiation therapy for the treatment of patients with brain metastases and the second is to combine sorafenib with temozolomide for primary brain tumors.

Eligibility criteria:
inclusion criteria: 1. patients requiring a minimum 2-week course of radiation therapy 2. age \> or = 18 3. all tumors of the central nervous system, or metastasis to the central nervous system. 4. measurable disease preferred but not required for eligibility 5. histologically or cytologically documented evidence of malignancy (for infratentorial and supratentorial glioma patients only). 6. radiographic evidence of brain metastasis 7. ecog performance status of 0 or 1 8. life expectancy of \> or = 3 months exclusion criteria: 1. patients receiving chemotherapy or other investigational drugs must be discontinued 14 days prior to enrollment. 2. cardiac disease: congestive heart failure \> class ii nyha. patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months. 3. cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. 4. uncontrolled hypertension defined as systolic blood pressure \> 150 mmhg or diastolic pressure \> 90 mmhg, despite optimal medical management. 5. known human immunodeficiency virus (hiv) infection or chronic hepatitis b or c. 6. active clinically serious infection \> ctcae grade 2

Keywords: sorafenib radiation therapy radiotherapy temozolomide brain metastases brain tumors
improvements in pneumonia status after oral care intervention in taiwan

Conditions: Pneumonia

Summary: the correlation between improvement in oral health, reduction in oral bacterial concentration, and status of pneumonia hospitalization remains unclear. to determine the effects of professional oral care intervention on the index of oral health, salivary and sputum bacterial concentrations, and pneumonia hospitalization status of nursing home residents using a quasi-experimental study. two nursing homes were on demand selected as the intervention and control groups; in the intervention group, weekly professional oral care was administered in addition to regular oral care by trained dental hygienists. demographic data and oral health status were analyzed. total salivary and sputum bacterial concentrations were determined using real-time polymerase chain reaction.


Eligibility criteria:
inclusion criteria: * informed consent * 51 year-old and above * being bedridden for ≥ 6 months * positive sputum production * difficulty in swallowing reported by caregivers exclusion criteria: * below 51 year-old * patients or family refused any oral care

Keywords: oral care intervention nursing home residents
a study comparing pemetrexed plus best supportive care versus best supportive care alone in the treatment of mesothelioma

Conditions: Mesothelioma

Summary: based on results from earlier clinical trials, pemetrexed may have antitumor activity as a first-line agent in the treatment of mesothelioma. given this, it is hypothesized that pemetrexed may be active in second-line mesothelioma in which the standard treatment is best supportive care. this study will compare survival of previously treated patients with malignant pleural mesothelioma who receive pemetrexed plus best supportive care to the survival of similar patients who receive best supportive care alone.


Eligibility criteria:
inclusion criteria: * histologically proven diagnosis of mesothelioma of the pleura. * received only one prior systemic chemotherapy regimen for advanced or metastatic disease * performance status of 70 or higher on the karnofsky performance status scale * males or females at least 18 years of age * adequate organ function exclusion criteria: * active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy * pregnancy or breastfeeding * brain metastasis * prior treatment with pemetrexed * inability or unwillingness to take folic acid or vitamin b12 supplementation
phase 1 study of daewon-es(b) & megace in healthy male volunteers under fed condition

Conditions: Healthy

Summary: the purpose of this study is to evaluate pharmacokinetics of daewon dw-es(b) 625mg/5ml and megace 800mg/20ml in healthy male volunteers under fed condition.


Eligibility criteria:
inclusion criteria: * adult males aged 20 to 40 years at screening. * no significant congenital/chronic disease. no symptoms in physical examination. * appropriate subjects as determined by past medical history, laboratory tests, serology and urinalysis. * be able to understand the objective, method of the study, the characteristics of investigational drug, and comply with the requirement of the study. subject must provide written informed consent prior to study participation exclusion criteria: * history or presence of liver, kidney, or nervous system disease, respiratory disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric or cognitive disorders. * history of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or disorders of absorption, distribution, metabolism, excretion. * history of taking megestrol
observatory of pulmonary arterial hypertension of congenital heart disease

Conditions: Pulmonary Arterial Hypertension of Congenital Heart Disease

Summary: the complex congenital cardiac malformations are a significant number of different diseases, each having specific natural histories. the interface with pulmonary arterial hypertension (htap) is high since the physiology of many of these disorders comprises alterations in pulmonary vasculature. this observatory is a cohort of 400 patients enrolled in 3 years, older than one month, having been informed and have agreed to participate in the study and with congenital heart disease other than patent foramen ovale as well as a diagnosis of pulmonary hypertension confirmed by cardiac catheterization. the main objectives of this report are to know * incidence of congenital heart disease in htap france. * describe the natural history of htap in a large population of patients congenital heart disease in france * the characteristics of htap congenital heart disease * having a cohort study


Eligibility criteria:
inclusion criteria: * the patient has a congenital heart disease other than patent foramen ovale * the diagnosis of pulmonary hypertension was confirmed by cardiac catheterization. only patients with eisenmenger syndrome can be included without catheterization. * the catheterization was done after 1 january 2009 * a mean pulmonary artery pressure \> 25 mm hg * pulmonary vascular resistances \> 3 piece wood m2 * pulmonary capillary pressure available * consent for inclusion in the study must be signed by parents or legal guardians for minors, by the patient for adults. * the patient he had a surgical procedure or interventional catheterization cardiac catheterization between his diagnosis and inclusion in the observatory? if yes, it can only be included if a new catheterization confirmed the persistence of htap at least 6 months after the procedure. * patient follow-up (at least once a year) in the center for its htap associated with congenital heart disease its
risk factors for the recurrent postoperative macular edema treated with ozurdex

Conditions: Macular Edema

Summary: patients who were diagnosed as postoperative cme and administrated with intravitreal ozurdex injection were reviewed. outcome will include best-corrected visual acuity (bcva), intraocular pressure (iop) and central macular thickness (cmt). recurrent cme and corresponding treatments were recorded.

patients who were diagnosed as postoperative cme after uneventful intraocular surgery and administrated with intravitreal ozurdex injection were reviewed. all patients underwent ophthalmic examinations at the initial visit and were followed up at months 1, 2, 3 and 6 with measurement of best-corrected visual acuity (bcva), intraocular pressure (iop) and central macular thickness (cmt). recurrent cme and corresponding treatments were recorded. risk factors of recurrent cme were analyzed

Eligibility criteria:
inclusion criteria: * patients who were diagnosed as postoperative cme after successful phacoemulsification or vitrectomy and administrated with intravitreal dexamethasone implant (ozurdex, allergan, inc, california, usa) injection were reviewed. exclusion criteria: * patients with retinal vascular diseases, including retinal vein occlusion (rvo), diabetic retinopathy (dr), hypertensive retinopathy, retinal artery occlusion (rao), coats disease, eales disease; * patients with macular disease before surgery, such as age-related macular degeneration (armd), macular choroidal neovascularization (cnv), myopic macular degeneration, macular hole (mh), epiretinal membrane(erm); * patients with uveitis before surgery, including anterior, intermediate, posterior and generalized uveitis; * patients with autoimmune disease, such as ankylosing spondylitis (as), vogt-koyanagi-harada (vkh) disease, behcet disease.
study to evaluate efficacy and safety of the topical product in patients with mild to severe scalp psoriasis

Conditions: Scalp Psoriasis

Summary: a randomized double-blind, vehicle-controlled, parallel design, multiple-site, phase iii clinical study

this randomized, double-blind, vehicle-controlled, parallel-group multiple-site study is designed to evaluate the therapeutic efficacy and safety of the investigational product, dsxs 1535 product, for the treatment of mild to severe scalp psoriasis

Eligibility criteria:
inclusion criteria: * patients with a clinical diagnosis of mild to severe plaque psoriasis of the scalp, defined by an investigator's global assessment (iga) score of at least 2 at baseline/randomization exclusion criteria: * patients whose scalp psoriasis necessitates systemic or other concomitant topical therapies during the study (concomitant treatment of body psoriasis with over the counter topical products including emollients, is allowed). * patient has a scalp skin condition that would interfere with the diagnosis or assessment of plaque psoriasis of the scalp (e.g., seborrheic dermatitis, eczema, cutaneous t-cell lymphoma, or other forms of psoriasis including guttate, inverse, pustular or erythrodermic psoriasis) * presence of pigmentation, extensive scarring, pigmented lesions, or sunburn in the treatment areas that could interfere with the rating of efficacy parameters, including planned extensive exposure to sunlight during the study. * history of psoriasis unresponsive to topical treatments. * current immunosuppression or history of organ transplant. * patients who have a history of or current diagnosis of glaucoma. * patients who have had surgery on the eyes or eyelids within 1 month before baseline or plan to have eye or eyelid surgery during the study. * patients with active infection (including but not limited to bacterial, fungal and viral infection) and/or open wounds on the entire head and neck area.
the effect of peer comparison emails on oncologists' documentation of cancer stage

Conditions: Oncology

Summary: documenting cancer stage is the most important determinant of treatment approach and survival for cancer patients. however, oncologists do not routinely document a patient's cancer stage in the structured field in electronic health records. this quality improvement pilot study evaluated the impact of sending an email to physicians at a cancer center of a large academic hospital with individualized data on their rates of cancer stage documentation using a structured field. the investigators assessed patient-level documentation and physician-level rates of staging documentation over 15 months including a three-month pre-period, a six-month pilot phase and a six-month follow-up period. the investigators also estimated staging documentation rates separately for each physician's new versus established patients.


Eligibility criteria:
inclusion criteria: * attending physicians who had been at one of three sites of hospital between january - august 2018 exclusion criteria: * physicians treating cancer patients where american joint committee on cancer (ajcc) staging modules were less clinically relevant * physicians with low clinical volume (\<5 patients over 3 months) * physicians without any outpatient visits
monocentric phase 1 study with escalation of doses of tocilizumab in combination with chemotherapy (idarubicin and cytarabine) in patients with acute myeloblastic leukemia (aml)

Conditions: Acute Myeloid Leukemia (AML)

Summary: this is a phase 1 dose escalation study testing the addition of an anti-il6 (tocilizumab) to standard induction chemotherapy for high-risk aml.

administration of tocilizumab at day 8 of induction following a classical induction using idarubicin 8mg/m2/d for 5 days and cytarabine 100mg/m2/d for 7 days.

Eligibility criteria:
inclusion criteria: - aml with a poor prognosis defined according to the criteria below: lam first line: age \ = 60 years old and intermediate or unfavorable risk according to the eln 2017 lam in relapse: whatever the age * ecog \<= 2 * patient eligible for intensive chemotherapy * informed consent * liver function tests: transaminases \<3x normal, bilirubin \<1.5x normal * creatinine clearance\> 60ml / min * lvef\> = 50% exclusion criteria: * uncontrolled infection * hep b, c, hiv + * history of diverticulosis / diverticulitis * no social security or any other scheme * pregnant women or patient unable to take contraception(contraceptive pill, abstinence, iud unauthorized) in case of fertility. a patient who cannot continue contraception for at least 3 months after the last injection of tocilizumab is not eligible. * lactating women * minors * adults under guardianship, curatorship or legal protection * hypersensitivity to one of the active substances or to one of the excipients * patients with tuberculosis * patients documented with active covid

Keywords: aml il-6 tocilizumab
scandinavian diverticulitis trial

Conditions: Diverticulitis

Summary: the purpose of this study is to determine whether laparoscopic lavage changes the rate of severe complications in patients with acute perforated diverticulitis who traditionally are treated with primary resection.

acute diverticulitis is a common disease in the western world. perforation of the acute diverticulitis with peritonitis is a feared complication and standard treatment (primary sigmoid resection such as hartmann's procedure) still has unsatisfactory results. both mortality and morbidity are quite high. several uncontrolled trials have reported a lower mortality and morbidity when acute perforated diverticulitis is treated with laparoscopic lavage instead of radical surgery. the investigators wish to conduct a randomized multicenter trial in scandinavia in order to compare the rates of severe postoperative complications in acute perforated diverticulitis if treated by traditional primary sigmoid resection or by laparoscopic lavage. the investigators are planning to include all patients admitted to the participating hospitals with clinical and radiological findings of acute perforated diverticulitis.

Eligibility criteria:
inclusion criteria: * age over 18 * clinical suspicion of perforated diverticulitis with indication for urgent surgery * ct scan with free air and findings suggesting diverticulitis * patient tolerates general anaesthesia * patients written consent exclusion criteria: * pregnancy * bowel obstruction
measuring analgesic interventions

Conditions: Pain

Summary: it is generally recognized that pain assessment and management especially in newborns, children and other nonverbal populations is an unmet need. according to the american medical association, "the pediatric population is at risk of inadequate pain management, with age-related factors affecting pain management in children. children are often given minimal or no analgesia for procedures that would routinely be treated aggressively in adults. although much is now known about pain management in children, it has not been widely or effectively translated into routine clinical practice". these two factors combine to emphasize the necessity for an objective tool to quantify pain and monitor the effectiveness of analgesia, especially during treatments. further, it is reported that many patients require a combination of treatments, and it is often necessary to test a variety of treatments before the personal match for treatment is found. the method in place to change the care on a subjective basis is difficult, time consuming, and not easily individualized. this pilot study is part of an ongoing effort to develop a method to objectively assess response to specific analgesic interventions. it specifically aims to discern the impact of analgesic interventions on sensory nerve fiber sensitivity in a diverse patient population.


Eligibility criteria:
inclusion criteria: 1. the subject is 7 to 21 years of age 2. the subject is receiving an analgesic intervention in the children's national medical center pain clinic 3. the subject is willing and able to provide written informed assent/parental consent to the study participation. exclusion criteria: 1. eye pathology precluding pupillometry 2. patients who are actively using opioids (history of use acceptable). rationale: opioids constrict the pupil, and therefore concomitant opioid use would bias our results. 3. subjects who are or may be pregnant

Keywords: analgesia pain nociception pupillometry analgesic
natriuretic peptide's headache inducing characteristics and effects on the cerebral blood flow

Conditions: Headache; Migraine

Summary: to investigate headache score and accompanying symptoms during and after infusion of the natriuretic peptides.


Eligibility criteria:
inclusion criteria: * healthy volunteers * aged 18-40 * 50-100 kg * fertile women must use safe contraceptives (iud, oral contraceptives, surgical sterilisation and long lasting gestagen. exclusion criteria: * tension type headache more than once/month * other primary headaches * daily medication except contraceptives * drug taken within 4 times the halflife for the specific drug except contraceptives * pregnant or lactating women * exposure to radiation within the last year * headache within the last 24 hours before start of trial * hypertension * hypotension * respiratory or cardiac disease
prevalence, severity and natural course of sleep apnea after cardiac surgery

Conditions: Sleep Disordered Breathing

Summary: sleep disordered breathing (sdb) is common in cardiovascular patients. patients after cardiac surgery will be screened for sdb with the apnoelink device at the beginning of cardiac rehabilitation and then after 3 weeks and 3 months.

objective(s) of the project * evaluate the prevalence of sleep apnea after cardiac surgery * compare results interindividually (group a vs. group b) and intraindividually (longitudinal assessment after 3 months) outcome(s) * prevalence of sleep apnoe at day 1 and 20 of rehabilitation and 3 months after cardiac surgery * composite endpoint of events at 3 months (cardiovascular death, non-fatal myocardial infarction, non-fatal cardiac arrest, revascularisation procedure, new atrial fibrillation and stroke) * change in 6-minute walking test (6-mwt) * impact of heart surgery on sleep apnoe

Eligibility criteria:
inclusion criteria: * cardiac surgery or orthopedic surgery \<2 weeks exclusion criteria: * known sdb